(Q73481981)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209899%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209899%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

A. Bergqvist

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9209899

1 September 2024

J. Jacobson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9209899

1 September 2024

S. Harris

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9209899

1 September 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9209899

1 September 2024

publication date

1 June 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209899%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

4 November 2019

https://www.tandfonline.com/doi/pdf/10.3109/09513599709152533

1 reference

https://api.crossref.org/works/10.3109/09513599709152533

Gynecological Endocrinology

1 September 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209899%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209899%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209899%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

187-194

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209899%20AND%20SRC:MED&resulttype=core&format=json

Gonadotropin-releasing hormone agonist plus estrogen-progestin "add-back" therapy for endometriosis-related pelvic pain

4 November 2019

cites work

1 reference

11 February 2024

https://opencitations.net/index/api/v1/citations/10.1016/S0015-0282(16)56090-7

Hypophysial Responses to Continuous and Intermittent Delivery of Hypothalamic Gonadotropin-Releasing Hormone

1

1 reference

https://api.crossref.org/works/10.3109/09513599709152533

"Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis

1 September 2024

2

1 reference

https://api.crossref.org/works/10.3109/09513599709152533

Gonadotropin-releasing hormone agonists and estrogen-progestogen replacement therapy

1 September 2024

3

1 reference

https://api.crossref.org/works/10.3109/09513599709152533

Low dose intranasal nafarelin for the treatment of endometriosis

1 September 2024

6

1 reference

https://api.crossref.org/works/10.3109/09513599709152533

Can hormone replacement therapy be used during medical therapy of endometriosis?

1 September 2024

7

1 reference

https://api.crossref.org/works/10.3109/09513599709152533

Steroidal and nonsteroidal "add-back" therapy: extending safety and efficacy of gonadotropin-releasing hormone agonists in the gynecologic patient

1 September 2024

10

1 reference

https://api.crossref.org/works/10.3109/09513599709152533

Revised American Fertility Society classification of endometriosis: 1985

1 September 2024

11

1 reference

https://api.crossref.org/works/10.3109/09513599709152533

Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial

1 September 2024

12

1 reference

https://api.crossref.org/works/10.3109/09513599709152533

A comparison of nafarelin acetate and danazol in the treatment of endometriosis

1 September 2024

13

1 reference

https://api.crossref.org/works/10.3109/09513599709152533

Long-term gonadotrophin-releasing hormone agonist therapy: the evolving issue of steroidal 'add-back' paradigms

1 September 2024

15

1 reference

https://api.crossref.org/works/10.3109/09513599709152533

Treatment of endometriosis with goserelin depot, a long-acting gonadotropin-releasing hormone agonist analog: endocrine and clinical results

1 September 2024

16

1 reference

https://api.crossref.org/works/10.3109/09513599709152533

Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up

1 September 2024

17

1 reference

https://api.crossref.org/works/10.3109/09513599709152533

The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism.

1 September 2024

18

1 reference

https://api.crossref.org/works/10.3109/09513599709152533

Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?

1 September 2024

20

1 reference

https://api.crossref.org/works/10.3109/09513599709152533

A randomized double blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone

1 September 2024

23

1 reference

https://api.crossref.org/works/10.3109/09513599709152533

Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin).

1 September 2024

24

1 reference

https://api.crossref.org/works/10.3109/09513599709152533

Hormone treatment of endometriosis: the estrogen threshold hypothesis

1 September 2024

26

1 reference

https://api.crossref.org/works/10.3109/09513599709152533

1 September 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209899%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference